[REVISION HISTORY]
vVardis NYSE initial public offering
1 recorded revision of this situation.
What changed
2026-11-14 00:45 UTC → 2026-11-14 14:56 UTC ·
added
removed
Swiss dental technology startup vVardis, which specializes in non-invasive treatments for early-stage tooth decay, initiated plans for an initial public offering on the New York Stock Exchange. The company sought a valuation of up to $4.37 billion, aiming to raise approximately $228.6 million through the sale of 9.5 million shares. Prior to its listing, the company raised $175 million by pricing 9.72 million shares at $18 per share. Co-founders and Co-CEOs Dr. Haley Abivardi and Dr. Goly Abivardi participated in discussions regarding the transition to a public entity on NYSE Live. Following the offering process, vVardis successfully listed on the New York Stock Exchange under the ticker VVVV. The company continues to focus on its flagship product, Curodont Repair Fluoride Plus, which uses proprietary peptide technology to support natural enamel remineralization without the need for drills, needles, or fillings.
Versions
- 2026-11-14 14:56 UTC vVardis NYSE initial public offering
- 2026-11-14 00:45 UTC vVardis NYSE initial public offering
Select a version to see what changed compared to the one before it.